CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 600 target
Drug / intervention
Raloxifene - Usual +1 moredrug
Likely dose
Raloxifene - Usual 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06062810
NCT06062810Phase 3ActiveOn TrackUpdated 2mo ago
CompareCT.gov

Explore the Relationship Between Single Nucleotide Polymorphisms and Raloxifene Response and Toxicity in Patients With Breast Cancer LCIS

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair·interventional·Posted Oct 2, 2023·Updated Apr 23, 2026

In Brief

A Phase 3 clinical trial evaluating Raloxifene - Usual and Raloxifene - Study for Breast Cancer. Active but no longer recruiting, targeting 600 participants across 1 site.

Detailed Summary

Explore the relationship between drug target ER gene single nucleotide polymorphisms and Raloxifene therapeutic effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target UGT gene single nucleotide polymorphisms and Raloxifene side-effects in patients with Breast Cancer LCIS, based on Oxford precisely sequencing drug targets' genes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 3Active
2024202520262027
First PostedOct 2, 2023
Enrollment StartJun 21, 2025
Primary CompletionDec 18, 2026
Study CompletionDec 28, 2026
TodayJul 1, 2026
Enrollment to primary: 1.5 yearsPosted 2.7 years agoPrimary completion in 6 months

Interventions

Raloxifene - Usualdrug

* Generic-1 - raloxifene hydrochloride tablet * Raloxifene 60 mg x 2 taken orally daily

Raloxifene - Studydrug

* Generic-2 - Raloxifene Hydrochloride Tablet * Raloxifene 60 mg x 2 taken orally daily